Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at BTIG Research in a report released on Thursday, Benzinga reports. They presently have a $8.00 target price on the stock. BTIG Research’s price target would suggest a potential upside of 230.58% from the company’s previous close.
Serina Therapeutics Stock Down 5.8%
Shares of Serina Therapeutics stock traded down $0.15 during trading hours on Thursday, reaching $2.42. 37,454 shares of the company’s stock were exchanged, compared to its average volume of 1,683,978. The stock has a market cap of $61.47 million, a P/E ratio of -1.28 and a beta of 1.18. The company has a 50 day moving average of $2.36 and a two-hundred day moving average of $2.05. Serina Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $5.83. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.16.
Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) earnings per share (EPS) for the quarter.
About Serina Therapeutics
Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.
Featured Articles
- Five stocks we like better than Serina Therapeutics
- Insider Sales Eclipse $450M Across 3 AI Winners, With NVIDIA Leading the Pack
- GameStop’s Comeback Case Is Getting Interesting, But eBay Still Looks Stronger
- Why Braze’s Guidance Miss May Be a Gift for Investors
- This Corner of the Market Is Outperforming the Benchmark—And It’s Not AI
Receive News & Ratings for Serina Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Serina Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
